Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
Apogee Therapeutics, Inc. furnished an earnings press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to this Current Report as Exhibit 99.1, and a Cover Page Interactive Data File is provided as Exhibit 104.
The filing states that the exhibit furnished under Item 2.02 is not deemed to be "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. The registrant is Apogee Therapeutics, Inc., incorporated in Delaware, trading on the Nasdaq Global Market under the symbol APGE.
Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), reported a sale of 2,725 shares of Apogee common stock on 08/06/2025 at a reported price of $37.78 per share. The transaction is recorded on a Form 4 and was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024, a plan described in the filing as intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
The filing shows that following the reported sale Mr. Dambkowski beneficially owned 236,273 shares, held directly. No derivative transactions are reported on this Form 4 and the document is limited to the single non-derivative sale and the related ownership position.
Apogee Therapeutics (APGE) filed an 8-K to disclose positive 16-week data from Part A of its Phase 2 APEX trial evaluating APG777, an anti-IL-13 antibody, in moderate-to-severe atopic dermatitis (AD). The randomized, placebo-controlled study (n = 123; 2:1 randomization) met its primary endpoint, delivering a 71.0% mean EASI score reduction versus 33.8% for placebo. Key secondary endpoints also favored APG777, with EASI-75 achieved by 66.9% of treated patients (24.6% placebo) and EASI-90 by 33.9% (14.7% placebo). Exposure-response analyses showed up to 89.5% EASI-75 in the highest drug-exposure quartile.
Safety appeared benign: TEAEs occurred in 56.1% of treated subjects versus 63.4% placebo, serious TEAEs were 1.2% vs 2.4%, and no injection-site reactions were reported. Common events—non-infective conjunctivitis, URTI, nasopharyngitis—were comparable or lower than placebo.
Next steps: Part B (≈280 pts, four-arm dose optimisation) is enrolling with 16-week data expected mid-2026, enabling a planned Phase 3 start in 2026. Maintenance data (3-/6-month dosing) from Part A are due 1H 2026. A separate Phase 1b head-to-head trial of APG279 versus Dupixent has begun, with readout 2H 2026.
The company will host a conference call on 7 July 2025 at 8:00 a.m. ET to review results. Exhibits 99.1 and 99.2 contain the full press release and deck; they are furnished, not filed.
Apogee Therapeutics (APGE) reported insider stock option grants to directors affiliated with Fairmount Funds Management. On June 17, 2025, two directors received identical stock option packages:
- Peter Harwin and Tomas Kiselak each received options to purchase 14,461 shares at an exercise price of $41.66 per share
- Options will vest on the one-year anniversary of the grant date (June 17, 2026)
- Options expire on June 17, 2035
Both directors hold these options on behalf of Fairmount Funds Management investment vehicles and must turn over any proceeds to Fairmount. Both directors disclaim beneficial ownership except for their pecuniary interest. Fairmount is deemed a director by deputization due to Harwin and Kiselak serving as both board members and Managing Members of Fairmount.
Apogee Therapeutics, Inc. (APGE) – Form 4 insider filing
On 17 June 2025, director Nimish P. Shah received a new stock-option grant covering 14,461 common shares. The option has an exercise price of $41.66, a 10-year term expiring 17 June 2035, and vests in full on the first anniversary of the grant date, contingent on continued service.
The filing lists the transaction as code “A” (acquired), indicating it is an original award rather than a market purchase. No non-derivative share transactions were reported, so Mr. Shah’s direct common-stock position is unchanged.
According to a pre-existing agreement, the option is deemed to be held for the sole benefit of VR Management, LLC. Consequently, both the reporting person and VR Management may be considered indirect beneficial owners. Mr. Shah disclaims beneficial ownership beyond any pecuniary interest.
- No cash consideration was paid for the option (price of derivative security reported as $0.00).
- Ownership is reported as Direct (D), subject to the indirect-beneficial-ownership disclaimer above.
The grant represents normal director compensation and does not, by itself, alter Apogee’s capital structure or have an immediate cash impact. Investor takeaway: routine alignment of director incentives with shareholder value; no material operational or financial effect.